Condition: Breast Cancer - Infiltrating Ductal Carcinoma · HER-2 Positive Breast Cancer · Sponsor: Legacy Health System
The usual approach to care for hormone receptor positive, HER2 positive breast cancer is chemotherapy and HER2 targeted therapy followed by endocrine therapy and surgery. The purpose of this Research Study is to see if taking endocrine therapy with the chemotherapy and HER2 directed therapy increases patients response to therapy at the time of surgery
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Legacy Mount Hood Medical Center | Gresham, Oregon, United States | Recruiting |
| Legacy Good Samaritan Medical Center | Portland, Oregon, United States | Recruiting |
| Legacy Meridian Park Medical Center | Tualatin, Oregon, United States | Recruiting |
| Legacy Salmon Creek Medical Center | Vancouver, Washington, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07506876